started · updated
Obesity treatments evolve toward weekly injections and oral therapies
Medical experts at the Italian Obesity Society's national congress in Palermo discussed the rapid evolution of obesity treatments. The field is transitioning from daily injections to weekly doses, with oral therapies on the horizon. Notably, the European Medicines Agency (EMA) has approved the molecule orforglipron, which is expected to reach commercial markets soon.
New obesity medications, specifically those based on incretins, offer benefits beyond weight loss, including improved cardiovascular health and reduced risks of fatty liver and sleep apnea. However, experts warn that obesity is a chronic condition; stopping treatment abruptly can lead to weight regain, necessitating long-term management alongside diet and exercise.
In Italy, where approximately 46% of adults are overweight or obese, access to these treatments remains a challenge due to high costs. While long-term safety is generally supported, ongoing studies continue to evaluate potential oncological risks.
Entities
European Medicines Agency · Lilly · Palermo · Paolo Sbraccia · Società Italiana dell'Obesità
Claims
What the coverage asserts, and how many sources carry each claim.
- [○ 1 SOURCE] Abruptly stopping obesity medication can lead to weight regain. www.stranotizie.it
- [● 2 SOURCES] Treatments have evolved from daily injections to weekly injections. www.liberoquotidiano.it · www.notizie.it
- [● 2 SOURCES] The first GLP-1 agonist drug was approved in Italy in 2015. www.liberoquotidiano.it · www.notizie.it
- [○ 1 SOURCE] Approximately 46% of adults in Italy are overweight or obese. www.stranotizie.it
- [● 2 SOURCES] The European Medicines Agency (EMA) committee has approved the molecule orforglipron. www.liberoquotidiano.it · www.notizie.it
- [○ 1 SOURCE] Obesity medications can improve cardiovascular conditions and reduce risks of fatty liver and sleep apnea. www.stranotizie.it